Please use this identifier to cite or link to this item:
Title: Dexamethasone in glioblastoma multiforme therapy : mechanisms and controversies
Authors: Cenciarini, Marta
Valentino, Mario
Belia, Silvia
Sforna, Luigi
Rosa, Paolo
Ronchetti, Simona
D’Adamo, Maria Cristina
Pessia, Mauro
Keywords: Glioblastoma multiforme
Nervous system -- Diseases
Issue Date: 2019
Publisher: Frontiers Media SA
Citation: Cenciarini, M., Valentino, M., Belia, S., Sforna, L., Rosa, P., Ronchetti, S., ... & Pessia, M. (2019). Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies. Frontiers in Molecular Neuroscience, 12.
Abstract: Glioblastoma multiforme (GBM) is the most common and malignant of the glial tumors. The world-wide estimates of new cases and deaths annually are remarkable, making GBM a crucial public health issue. Despite the combination of radical surgery, radio and chemotherapy prognosis is extremely poor (median survival is approximately 1 year). Thus, current therapeutic interventions are highly unsatisfactory. For many years, GBM-induced brain oedema and inflammation have been widely treated with dexamethasone (DEX), a synthetic glucocorticoid (GC). A number of studies have reported that DEX also inhibits GBM cell proliferation and migration. Nevertheless, recent controversial results provided by different laboratories have challenged the widely accepted dogma concerning DEX therapy for GBM. Here, we have reviewed the main clinical features and genetic and epigenetic abnormalities underlying GBM. Finally, we analyzed current notions and concerns related to DEX effects on cerebral oedema, cancer cell proliferation and migration and clinical outcome.
Appears in Collections:Scholarly Works - FacM&SPB

Files in This Item:
File Description SizeFormat 
1. Dexamethasone in Glioblastoma Multiforme Therapy. Mechansims and controversies..pdf1.43 MBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.